Therapy-related acute promyelocytic leukemia (t-APL) with the t(15;17) translocation is a well-recognized complication of cancer treatment with agents targeting topoisomerase II. However, cases are emerging following mitoxantrone therapy for multiple sclerosis (MS). Analysis of 12 cases of mitoxantrone-related t-APL in MS patients revealed an altered distribution of chromosome 15 breakpoints compared to de novo APL, biased towards disruption within PML intron 6 (11/12, 92% vs 622/1022, 61%: p=0.035). Despite this intron spanning ~1kb, the breakpoint in five mitoxantrone-treated patients fell within an 8bp region (1482-9) corresponding to the "hotspot" previously reported in t-APL complicating mitoxantrone-containing breast cancer therapy. Another shared breakpoint was identified within the ~17kb RARA intron 2 involving two t-APL cases arising after mitoxantrone treatment for MS and breast cancer, respectively. Analysis of PML and RARA genomic breakpoints in functional assays in 4 cases, including the shared RARA intron 2 breakpoint at 14446-49, confirmed each to be preferential sites of topoisomerase IIα−mediated DNA cleavage in the presence of mitoxantrone. This study further supports the presence of preferential sites of DNA damage induced by mitoxantrone in PML and RARA genes that may underlie the propensity to develop this particular subtype of leukemia following exposure to this agent.
Introduction
The occurrence of acute promyelocytic leukemia (APL) as a second tumor (sAPL) frequently has been reported as a late complication of chemotherapy and/or radiotherapy (therapy-related APL, t-APL), although sAPL cases arising in patients whose primary tumors were treated by surgery alone have also been described [1] [2] [3] .
The agents most often associated with development of t-APL induce DNA damage through targeting of topoisomerase II, with mitoxantrone, epirubicin, adriamycin and etoposide being most commonly implicated [3, 4] . The latency period between chemotherapy exposure and the onset of t-APL is relatively short (<3 years) and typically occurs without a preceding myelodysplastic phase [3, 4] . In a study by Mistry et al [5] concerning molecular mechanisms underlying formation of the t(15;17) in t-APL, breakpoints in cases arising following mitoxantrone exposure for prior breast carcinoma were found to be clustered in an 8bp region within PML intron 6; this corresponded in functional assays to a preferential site of mitoxantrone-induced topoisomerase II-dependent cleavage at position 1484. Although these findings highlighted the leukemogenic role of druginduced DNA cleavage at specific sites in the genome, the precise mechanism by which secondary leukemias with balanced chromosomal translocations such as the t(15;17) in APL develop remains controversial [6] [7] [8] [9] . This is compounded by the fact that many patients have been exposed to multiple cytotoxic drugs often accompanied by radiotherapy, making it difficult to categorically ascribe the etiology of therapy-related AML (t-AML) in any given case.
Previous studies on t-AML have focused on patient populations that feasibly could have been enriched for individuals at particular risk of leukemia, having already developed one form of cancer. Therefore, to investigate whether particular
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From chemotherapeutic agents have a propensity to induce specific molecular subtypes of t-AML, it is of interest to study patients exposed to topoisomerase II targeting drugs used in the treatment of non-malignant conditions, such as mitoxantrone in the management of multiple sclerosis (MS). MS is a putative autoimmune disease affecting the central nervous system for which mitoxantrone represents the latest in a long list of general immunosuppressive agents used in the treatment of this condition [10, 11] . In recent years, an increasing number of APL cases have been reported in MS patients treated with mitoxantrone [3, 5, [12] [13] [14] [15] [16] [17] [18] [19] [20] . However, to date no attempts have been made to systematically characterize translocation breakpoints in APL cases that developed in this setting.
In the present study, we analyzed at the genomic level the PML and RARA breakpoints of 14 patients who developed APL on a background of MS, including 12 who received mitoxantrone for their primary disease. Furthermore, we used functional cleavage assays to better elucidate the mechanisms underlying the formation of the t(15;17) in this setting.
Material and Methods

Patients and samples
The main patient characteristics, including demographic data, MS type, and treatments received for MS, are reported in Table 1 To determine the exact chromosomal breakpoint position in PML and RARA genes, genomic DNA extracted from APL blasts collected at diagnosis was amplified by a two step long-range nested PCR method as reported elsewhere [5, 21] . Two forward and eight reverse primers were designed for each step to cover the PML breakpoint region (bcr1 or bcr3, as previously known based on diagnostic RT-PCR results available for all cases) and the 16.9 kb long RARA intron 2. PCR products were purified using the QIAquick PCR purification kit (Qiagen, Valencia CA).
Samples were loaded in 96-well plates and covered with mineral oil. The amplified products were separated with a capillary electrophoresis-based system (CEQ 8000 Genetic Analysis system, Beckman Coulter) using the 'LFR1 Test' default run method and sequenced using appropriate primers [5, 21] . Rigorous procedures were employed to reduce risk of PCR contamination [22] , and genomic breakpoints were in all cases confirmed by PCR analysis of a fresh aliquot of DNA. Moreover, in 3 cases, breakpoint analyses were performed independently in parallel in the Rome and London laboratories, yielding identical results.
Amplification and sequence analysis of the reciprocal RARA-PML genomic breakpoint junction
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Genomic RARA-PML was amplified using patient specific primers (designed on the basis of PML and RARA breakpoints) and fresh aliquots of DNA. In 13 cases, the reciprocal RARA-PML genomic breakpoint junction was sequenced, providing further confirmation of the t(15;17) translocation breakpoints at the genomic level. In one case (UPN 10), no DNA was available to carry out sequencing of the reciprocal
RARA-PML.
Alignment of sequenced nucleotides using BLAST algorithm
Patient's genomic PML-RARA junction sequences were aligned against normal PML (GenBank accession number S57791 for bcr1 and S51489 for bcr3) and RARA intron 2 (GenBank accession number AJ297538) nucleotides as a reference text input in BLAST/alignment program. The purpose of alignment was to identify any microhomologies between PML and RARA in the vicinity of the breakpoint.
In vitro DNA cleavage assays
Human topoisomerase IIα was expressed in Saccharomyces cerevisiae [23] and purified as described previously [24] [25] . Assays were performed as described previously [5] . Briefly, having identified genomic junction sequences, regions of the normal homologues encompassing the breakpoint sites were amplified by PCR and subcloned into the pBluescript SKII(+) vector. The optimal insert size for the assay was 200-500 bp, with the breakpoint site located approximately 50-100 bp from the 5' end of the insert. Substrates containing 25 ng of the normal homologues of the translocation breakpoints were 5'end-labelled (30,000 cpm) and incubated with 147nM human DNA topoisomerase IIα, 1mM ATP in the presence or absence of 20 µM mitoxantrone [5] . In all cases, additional reactions were carried out to evaluate the For personal use only. on November 16, 2017. by guest www.bloodjournal.org From heat stability of the covalent complexes formed. Cleavage complexes were irreversibly trapped by the addition of sodium dodecyl sulfate (SDS) and purified products were resolved in an 8% polyacrylamide-7.0M urea gel in parallel with dideoxy sequencing reactions primed at the same 5'-end, visualized by autoradiography and quantified using PhosphoImager and IMAGEQUANT software (Molecular Dynamics).
Results
Clinical features
As shown in Table 1 , a total of 14 patients with APL developing in a background of MS were studied. The series included 12 cases exposed to a median total dose of 105 mg mitoxantrone (range 30-234 mg), while 2 patients received other treatments for their primary disease (interferon beta in UPN 10 and corticosteroids in UPN 12). The median latency period between the first exposure to mitoxantrone and APL diagnosis was 28 months (range 4-60 months). Patients were treated with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy, mostly using AIDA-like (ATRA+Idarubicin) protocols [26] (Table 2) ; however, UPN 13 died of cerebral hemorrhage within 3 hrs of APL diagnosis before anti-leukemic therapy was started. The remaining 13 patients achieved hematologic and molecular remission. Of these, 11 remain in first molecular remission at a median follow-up of 10 months, while UPN 7 relapsed at 28 months and achieved second molecular remission after salvage therapy with arsenic trioxide, and UPN 1 died of cerebral hemorrhage while in remission after 7 months.
Location of t(15;17) translocation breakpoints within the PML and RARA loci
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From RT-PCR showed the bcr1 PML-RARA isoform (PML intron 6 breakpoint) in 12 cases, while in the remaining two cases the PML breakpoint fell within intron 3 (bcr3) (Figure 1 ). This breakpoint distribution appeared skewed in favor of the bcr1 isoform, which previously has been reported to account for approximately 55% of unselected APL cases [27] [28] [29] . Comparison of the breakpoint distribution in MS patients with mitoxantrone-related APL relative to a cohort of 1022 consecutive cases of newly diagnosed de novo APL from GIMEMA, PETHEMA and UK MRC trials confirmed significant over-representation of involvement of PML intron 6 in the former group (11/12, 92% vs 622/1022, 61%: p=0.035 by Fisher exact test). PML genomic breakpoints within intron 6 were found to fall between nucleotide positions 1482 and 1489 in six patients (UPN 3, 6, 11, 12, 13 and 14) ( Figure 1A ), coinciding precisely with the "hotspot" previously identified in t-APL following mitoxantrone treatment for breast cancer [5] . Interestingly, one of these patients (UPN 12) had not received mitoxantrone therapy for MS. In the two patients (UPN 9 and 10) with the bcr3 PML-RARA isoform, the breakpoints in PML intron 3 were detected between nucleotides 1286-1287 and 1117-1122 respectively ( Figure 1A ). The breakpoints within the RARA locus were distributed across intron 2 without particular clustering in any restricted small region ( Figure 1B ). However, one breakpoint (in UPN 2) mapped precisely to a breakpoint found in a case of t-APL arising following mitoxantrone therapy for breast cancer, studied previously by Mistry et al [5] .
Sequence analyses of the reciprocal RARA-PML fusion revealed a balanced translocation in 7 of 13 analyzed cases. Six patients showed size variable deletions and/or insertions at the breakpoint junction (Table 1 ). Microhomologies at the breakpoint junctions were indicative of DNA repair by the non-homologous endjoining (NHEJ) pathway [5] . In order to investigate the mechanisms by which the t(15;17) chromosomal translocation may have been formed in MS patients treated with mitoxantrone, we evaluated topoisomerase IIα−mediated cleavage of the normal homologues of PML and RARA encompassing the respective breakpoints detected in four cases (UPN 2, 7, 8 and 14) in the presence or absence of this agent. These included cases (i.e. UPN 2 and UPN 14) in which the genomic breakpoint in the RARA or PML locus coincided with those reported previously in cases of t-APL arising in breast cancer patients treated with multiple DNA-damaging agents including mitoxantrone [5] . Few cleavage sites were observed in the absence of drug; however, bands of various sizes and intensities were observed in the presence of mitoxantrone in a topoisomerase IIα-dependent manner (Figures 2 and 3, upper panels). Cleavage bands that were significantly enhanced by mitoxantrone corresponding to the location of the observed genomic breakpoints in the PML and RARA loci were detected in each of the cases analyzed (Figures 2 and 3 , panels A and B, and data not shown). These bands remained detectable after heating, indicating stability of the cleavage complexes. In UPN 2, the case in which the RARA breakpoint was shared with a t-APL case that arose after mitoxantrone-containing breast cancer therapy [5] , a functional site of mitoxantrone-induced cleavage by topoisomerase II was identified at position 14444 (Figure 2, panel B) .
In order to provide further evidence that the region between positions 1482 and 1489 within PML intron 6 (which was involved in almost half the cases) is also a For personal use only. on November 16, 2017. by guest www.bloodjournal.org From preferential site of mitoxantrone-induced DNA cleavage mediated by topoisomerase IIα, the reverse complement of the described PML substrate [5] was used in the cleavage assay. A strong heat-stable cleavage band was detected in the presence of mitoxantrone at position 1488, which corresponds to the described functional cleavage at position 1484 on the upper strand Based upon sequence analysis of PML-RARA and reciprocal RARA-PML genomic breakpoints, the location of functional topoisomerase IIα cleavage sites in the vicinity of the breakpoints, and known mechanisms by which topoisomerase II induces double-strand breaks in DNA [30] and their subsequent repair [6] , it was possible to generate models as to how the t(15;17) chromosomal translocation could have been formed in the studied cases (Figure 2 and 3, panel C). Type II topoisomerases introduce staggered nicks in DNA creating 5'−overhangs. In the models, repair of the overhangs in PML and RARA entails exonucleolytic digestion, pairing of complementary bases, and joining of DNA free ends by the NHEJ pathway, with template-directed polymerization to fill in any gaps.
Discussion
In this study on sAPL that developed after MS, we were able to identify a biased distribution of breakpoints in the PML gene that clustered in the same
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From "hotspot" region previously identified in APL cases arising following treatment with mitoxantrone for breast cancer [5] . In addition, we established in one patient that the breakpoint in RARA intron 2 at position 14446-49 coincided with a breakpoint identified by Mistry et al in 1 of 5 t-APL cases arising in breast cancer patients treated with the same agent [5] . Given that intron 2 is almost 17 kb in length, such tight clustering of breakpoints between two different t-APL cases would be highly unlikely to occur by chance. This observation strongly suggests that this is a preferential site of mitoxantrone-induced cleavage of DNA by topoisomerase IIα. The hypothesis is further supported by our functional in vitro data that show that this RARA site, together with the previously identified 8 bp 'hotspot' region in PML intron 6, are preferential targets of mitoxantrone-induced DNA damage mediated by topoisomerase IIα.
Interestingly, of the 6 patients found to have PML breakpoints involving the 'hotspot' region, one (UPN 12) did not receive mitoxantrone. While mitoxantrone may significantly increase the chances of inducing DNA damage at this site, it is conceivable that this region represents a preferential site of cleavage by the native topoisomerase IIα and which could in some instances act in concert with environmental or dietary agents that also target the enzyme [31] [32] [33] [34] [35] . Accordingly, in the other case of sAPL that arose in the absence of mitoxantrone exposure (UPN 10), the in vitro DNA cleavage assay also revealed sites of cleavage in the PML and RARA substrates with topoisomerase II alone which corresponded to the observed breakpoints (data not shown).
In some cases, the occurrence of short homologies of 1 or 2 nucleotides at the breakpoint region between the PML and RARA genes precluded precise assignment of the breakpoint within each respective gene. However, further [30] and the processes mediating their repair, most likely involving the NHEJ pathway [5, 29] it was possible to model the generation of the t(15;17) chromosomal translocation underlying the development of APL in these cases. Previous studies have established the presence of functional topoisomerase II cleavage sites at translocation breakpoints in MLL-associated t-AML, indicating that direct DNA damage coupled with aberrant repair by the NHEJ pathway is likely to be relevant to the formation of translocations that disrupt other genes that are commonly involved in t-AML [36] [37] [38] .
To the best of our knowledge, 20 cases of sAPL occurring in patients with MS have been reported to date [3, 5, [12] [13] [14] [15] [16] [17] [18] [19] [20] , four of which are included in the present series (UPN 1, 4, 5 and 7) [5, 17 , 20] . However, this is the first study to systematically analyze such cases at the genomic level. The incidence of sAPL arising in MS patients treated with mitoxantrone is not firmly established, as no systematic analysis has been undertaken to address this issue and only case reports have been published.
On reviewing the records of 2336 MS patients treated with mitoxantrone, Voltz et al [39] described five cases of t-AML and two sAPL as a case report. Ghalie et al [40] assembled the records of 1378 patients treated with mitoxantrone in 3 MS studies and reported 2 patients who developed t-AML with an observed incidence proportion of 0.15% (95% confidence interval = 0.00 -0.40%). In addition to the reported 20 cases of sAPL, 8 cases of t-AML (non M3) arising after mitoxantrone treatment for MS have been described with the majority showing balanced translocations in their leukemic cells [39, [41] [42] [43] [44] [45] . Therefore, while it appears that an excess of sAPL cases are
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From observed in the MS setting, the reasons underlying this phenomenon remain unclear at present and warrant further basic and epidemiologic investigation. It is unknown, for example, whether factors other than mitoxantrone may play a role in sAPL development in the context of MS. Finally, it would be important to assess prospectively the true incidence of APL development in the MS setting (with or without mitoxantrone). Considering the risk of leukemia development and cardiac toxicity, the therapeutics and technology subcommittee of the American Academy of Neurology recently has recommended that mitoxantrone be reserved for patients with progressive MS who have failed other therapies [46] . In summary, this study lends further support to the presence of preferential sites of DNA damage induced by mitoxantrone within PML intron 6, and suggests the existence of a further "hotspot" at the distal end of RARA intron 2. The susceptibility of these regions of the PML and RARA loci to topoisomerase IIα−mediated cleavage by mitoxantrone may underlie the propensity to develop this particular subtype of AML following exposure to this agent. Further studies are warranted to investigate whether MS patients have a particular predisposition to the development of sAPL. DNA cleavage assays are shown for PML (A) and RARA (B) genomic breakpoint regions. For the PML assay the reverse complement of the substrate containing the "hotspot" region between 1482-9 described by Mistry et al [5] was used. Lanes 1-9 of each cleavage assay are described in the legend to Figure 2 . (C) Native PML and RARA sequences are shown in red and blue respectively. In the creation of PML-RARA, processing includes exonucleolytic deletion and repair via the NHEJ pathway. In the creation of RARA-PML, two base homologies facilitate repair via the NHEJ pathway, while in both instances polymerization of the relevant overhangs fills in any remaining gaps (shown in black font).
